TipRanks
Advertisement
Advertisement
Heron Therapeutics Extends Tax Benefit Preservation Plan Timeline
PremiumCompany AnnouncementsHeron Therapeutics Extends Tax Benefit Preservation Plan Timeline
2M ago
Heron Therapeutics downgraded to Neutral from Buy at H.C. Wainwright
Premium
The Fly
Heron Therapeutics downgraded to Neutral from Buy at H.C. Wainwright
2M ago
Heron Therapeutics Faces Nasdaq Delisting Risk as Share Price Falls Below $1 Threshold
Premium
Company Announcements
Heron Therapeutics Faces Nasdaq Delisting Risk as Share Price Falls Below $1 Threshold
2M ago
Heron Therapeutics price target lowered to $2 from $4 at H.C. Wainwright
PremiumThe FlyHeron Therapeutics price target lowered to $2 from $4 at H.C. Wainwright
5M ago
Heron Therapeutics Appeals Ruling Invalidating CINVANTI Patents
Premium
Company Announcements
Heron Therapeutics Appeals Ruling Invalidating CINVANTI Patents
5M ago
Heron Therapeutics downgraded at Needham after Cinvanti patents invalidated
Premium
The Fly
Heron Therapeutics downgraded at Needham after Cinvanti patents invalidated
5M ago
Heron Therapeutics price target lowered to $4 from $6 at H.C. Wainwright
PremiumThe FlyHeron Therapeutics price target lowered to $4 from $6 at H.C. Wainwright
5M ago
Heron Therapeutics reports Q1 EPS (4c), consensus (2c)
Premium
The Fly
Heron Therapeutics reports Q1 EPS (4c), consensus (2c)
5M ago
Heron Therapeutics backs FY26 revenue view $173M-$183M, consensus $174.73M
Premium
The Fly
Heron Therapeutics backs FY26 revenue view $173M-$183M, consensus $174.73M
5M ago

Trending

Name
Price
Price Change
S&P 500
―
Dow Jones
―
Nasdaq 100
―